ConvaTec Group PLC
LSE:CTEC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Custodian REIT PLC
LSE:CREI
|
UK |
|
A
|
American National Bankshares Inc
XBER:NBR
|
US |
|
Vivid Seats Inc
NASDAQ:SEAT
|
US |
|
Ryman Healthcare Ltd
NZX:RYM
|
NZ |
EBITDA Margin
EBITDA Margin shows how much profit a company makes from its core operations before accounting for interest, taxes, and depreciation. It helps assess how efficiently the company runs its main business.
EBITDA Margin shows how much profit a company makes from its core operations before accounting for interest, taxes, and depreciation. It helps assess how efficiently the company runs its main business.
Peer Comparison
| Country | Company | Market Cap |
EBITDA Margin |
||
|---|---|---|---|---|---|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.3B GBP |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
9.3T JPY |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
29.4B CHF |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
35.9B USD |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
99.8B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.2B USD |
Loading...
|
|
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
931.6B JPY |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.8B USD |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
38.5B CNY |
Loading...
|
|
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
38B CNY |
Loading...
|
|
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
4.9B USD |
Loading...
|
Market Distribution
| Min | -182 253.3% |
| 30th Percentile | 0.1% |
| Median | 0.2% |
| 70th Percentile | 0.3% |
| Max | 6 324.9% |
Other Profitability Ratios
ConvaTec Group PLC
Glance View
ConvaTec Group PLC is a notable player in the realm of medical products and technologies, deftly weaving its narrative within the healthcare industry. Founded in 1978, the company has steadily established itself through strategic expansion and innovation, focusing on improving the lives of patients and enhancing healthcare delivery. The company's core business revolves around four main product categories: Advanced Wound Care, Ostomy Care, Continence and Critical Care, and Infusion Care. Each of these sectors is backed by a robust commitment to research and development, allowing ConvaTec to deliver specialized products that cater to both specific patient needs and broader healthcare system demands. ConvaTec's financial model centers around providing essential, high-quality medical solutions that ultimately support improved patient outcomes. The company garners revenue by partnering with hospitals, healthcare providers, and direct consumer channels, ensuring its products reach where they are most needed. With a global footprint spanning multiple continents, ConvaTec not only distributes its products widely but also adapts its strategy to meet the nuanced requirements of diverse markets. By aligning itself closely with caregivers and leveraging cutting-edge technology, the company maintains a sustainable economic engine through both recurring sales from consumables and long-term relationships with its institutional clients.
See Also
EBITDA Margin is calculated by dividing the EBITDA by the Revenue.
The current EBITDA Margin for ConvaTec Group PLC is 25.5%, which is above its 3-year median of 23.9%.
Over the last 3 years, ConvaTec Group PLC’s EBITDA Margin has increased from 21.9% to 25.5%. During this period, it reached a low of 21.7% on Jun 30, 2023 and a high of 25.5% on Jan 1, 2026.